Simcere Pharma repurchases 1.64 million shares; cumulative buy-backs rise to 24.13 million

Bulletin Express

May 19

Simcere Pharmaceutical Group Limited (Simcere Pharma, HKEX: 02096) filed a Next Day Disclosure Return on 19 May 2026, reporting further progress under its on-market share repurchase programme.

The company bought back 1.64 million ordinary shares on 19 May 2026, paying a total of HK$17.99 million at prices between HK$10.7713 and HK$11.03 per share.

Including this latest transaction, 24.13 million shares purchased since 12 January 2026 remain pending cancellation. This volume equals 0.97% of the issued share capital on the date the current mandate was granted (13 June 2025).

Simcere Pharma is authorised to repurchase up to 247.47 million shares under the existing mandate; 9.75% of that limit has now been utilised. A 30-day moratorium on new share issues or disposals of treasury shares runs through 18 June 2026, in accordance with Hong Kong listing rules.

The company’s issued share capital stood unchanged at 2.60 billion shares as of 19 May 2026, with no treasury shares on hand. All repurchased shares are designated for cancellation upon settlement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1167663741"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167663741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167663741?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167663741","market":"us","top_or_hot":-1,"title":"Simcere Pharma repurchases 1.64 million shares; cumulative buy-backs rise to 24.13 million","media":"Bulletin Express","content":"<p>Simcere Pharmaceutical Group Limited (Simcere Pharma, HKEX: 02096) filed a Next Day Disclosure Return on 19 May 2026, reporting further progress under its on-market share repurchase programme.</p>\n<p>The company bought back 1.64 million ordinary shares on 19 May 2026, paying a total of HK$17.99 million at prices between HK$10.7713 and HK$11.03 per share.</p>\n<p>Including this latest transaction, 24.13 million shares purchased since 12 January 2026 remain pending cancellation. This volume equals 0.97% of the issued share capital on the date the current mandate was granted (13 June 2025).</p>\n<p>Simcere Pharma is authorised to repurchase up to 247.47 million shares under the existing mandate; 9.75% of that limit has now been utilised. A 30-day moratorium on new share issues or disposals of treasury shares runs through 18 June 2026, in accordance with Hong Kong listing rules.</p>\n<p>The company’s issued share capital stood unchanged at 2.60 billion shares as of 19 May 2026, with no treasury shares on hand. All repurchased shares are designated for cancellation upon settlement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharma repurchases 1.64 million shares; cumulative buy-backs rise to 24.13 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharma repurchases 1.64 million shares; cumulative buy-backs rise to 24.13 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-19 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Simcere Pharmaceutical Group Limited (Simcere Pharma, HKEX: 02096) filed a Next Day Disclosure Return on 19 May 2026, reporting further progress under its on-market share repurchase programme.</p>\n<p>The company bought back 1.64 million ordinary shares on 19 May 2026, paying a total of HK$17.99 million at prices between HK$10.7713 and HK$11.03 per share.</p>\n<p>Including this latest transaction, 24.13 million shares purchased since 12 January 2026 remain pending cancellation. This volume equals 0.97% of the issued share capital on the date the current mandate was granted (13 June 2025).</p>\n<p>Simcere Pharma is authorised to repurchase up to 247.47 million shares under the existing mandate; 9.75% of that limit has now been utilised. A 30-day moratorium on new share issues or disposals of treasury shares runs through 18 June 2026, in accordance with Hong Kong listing rules.</p>\n<p>The company’s issued share capital stood unchanged at 2.60 billion shares as of 19 May 2026, with no treasury shares on hand. All repurchased shares are designated for cancellation upon settlement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1167663741","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167663741","pubTimestamp":1779188608,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Simcere Pharmaceutical Group Limited (Simcere Pharma, HKEX: 02096) filed a Next Day Disclosure Return on 19 May 2026, reporting further progress under its on-market share repurchase programme. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"先声药业回购164万股；累计回购增至2413万笔","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"Simcere Pharmaceutical Group Limited (Simcere Pharma, HKEX: 02096) filed a Next Day Disclosure Return on 19 May 2026, reporting further progress under its on-market share repurchase programme.\nThe company bought back 1.64 million ordinary shares on 19 May 2026, paying a total of HK$17.99 million at prices between HK$10.7713 and HK$11.03 per share.\nIncluding this latest transaction, 24.13 million shares purchased since 12 January 2026 remain pending cancellation. This volume equals 0.97% of the issued share capital on the date the current mandate was granted (13 June 2025).\nSimcere Pharma is authorised to repurchase up to 247.47 million shares under the existing mandate; 9.75% of that limit has now been utilised. A 30-day moratorium on new share issues or disposals of treasury shares runs through 18 June 2026, in accordance with Hong Kong listing rules.\nThe company’s issued share capital stood unchanged at 2.60 billion shares as of 19 May 2026, with no treasury shares on hand. All repurchased shares are designated for cancellation upon settlement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}